|
SEARCH
|
INGELVAC CIRCOFLEX®
THE CONFIDENCE OF A SOUND ROI
Now more than ever, hog producers are demanding the highest possible return on investment for every production decision they make.
That’s why so many have chosen Ingelvac CircoFLEX® to protect their herds against the devastating impact of PCVAD (circovirus). It works fast and goes the distance.
SUBCLINICAL ROI: 4.38 to 11
In a blinded study conducted at a commercial operation with subclinical PCVAD, pigs vaccinated with Ingelvac CircoFLEX performed better than non-vaccinates, having fewer culls, higher weight gains and improved carcass traits. The calculated return on investment was 4.38 to 1.
CLINICAL ROI: 9.85 to 12
In a recent study using Ingelvac CircoFLEX in a clinical PCVAD setting, the economic benefits were even more dramatic. Pigs vaccinated at 3 weeks and 6 weeks both had significant reductions in mortality, culls and viral loads, with significant improvement in ADG and final body weight.
In another study of 600 pigs within a subclinical setting, a right shift and narrowing of weight range distribution illustrates the biologic and obvious economic benefits of Ingelvac CircoFLEX.3
Click here to see this webpage as a PDF.
References
1. King, D., Biologic benefits of controlling subclinical PCVAD with vaccination, AASV, 2008.
2. Cline, G., Wilt, V., Diaz, E., Efficacy of Ingelvac CircoFLEX in pigs vaccinated at 3 and 6 weeks of age in a PRRS and Mycoplasma hyopneumoniae-negative production system, Leman Conference 2007.
3. Waddell, J., Field evaluation of Ingelvac CircoFLEX on growth performance of pigs in a subclinical PCVAD herd, World Pork Expo, 2009.
